Since 2010, annual antimicrobial sales in Slovenia have fluctuated but a downward trend has been observed. The highest annual sales figures were 46.8 mg/PCU in 2010 and the lowest were 22.3 mg/PCU in 2013. Overall sales in 2020 (33.3 mg/PCU) were 28.8% lower than in 2010. The downward trend in sales across

No sales of other quinolones reported in 2017 and 2018.

* The class ‘Others’ includes sales of bacitracin, novobiocin, rifaximin and spectinomycin (classified as ‘Other antibacterials’ in the ATCvet system).
the study period applied to most antimicrobial classes, although an upward trend was observed for sales of tetracyclines and aminoglycosides.

Sales (mg/PCU) of 3rd- and 4th-generation cephalosporins fluctuated from 2010 to 2020. In 2010, this subclass accounted for 0.2% (0.11 mg/PCU) of total sales, while for 2020, the figure was 0.7% (0.22 mg/PCU) and the aggregated sales for the 25 countries were 0.16 mg/PCU.

Throughout the observation period, greater fluctuations were noted in sales of fluoroquinolones than in those of the other classes presented, with a peak in 2011 (5.94 mg/PCU) and a trough in 2020 (0.99 mg/PCU). Aggregated sales for the 25 countries in 2020 were 2.21 mg/PCU. In 2010, fluoroquinolones accounted for 5.5% of total sales, while the corresponding figure for 2020 was 3%.

Sales of other quinolones fell by 99.8% in 2020 (0.0003 mg/PCU) in comparison with 2010 (0.15 mg/PCU). No sales of other quinolones were reported for 2017 and 2018.

Sales (mg/PCU) of polymyxins fluctuated from 2010 to 2020, with a peak in 2018 (0.21 mg/PCU) and a trough in 2013 (0.04 mg/PCU). In 2010, this subclass accounted for 0.1% of total sales, while for 2020, the figure was 0.3%. In 2020, sales of polymyxin VMPs were 0.09 mg/PCU, while aggregated sales for the 25 countries in that year were 2.58 mg/PCU.

A fact-finding mission was carried out in Slovenia between 7 and 11 March 2016 in order to gather information on the prudent use of antimicrobials in animals\(^1\).

---